Century Therapeutics (NASDAQ:IPSC – Get Free Report) and Abcam (NASDAQ:ABCM – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, profitability, valuation and earnings.
Risk and Volatility
Century Therapeutics has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Comparatively, Abcam has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.
This is a breakdown of current ratings and target prices for Century Therapeutics and Abcam, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Earnings and Valuation
This table compares Century Therapeutics and Abcam’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Century Therapeutics||$5.20 million||15.88||-$130.93 million||($2.19)||-0.63|
|Abcam||$447.49 million||12.26||-$10.51 million||N/A||N/A|
Abcam has higher revenue and earnings than Century Therapeutics.
Insider and Institutional Ownership
32.3% of Century Therapeutics shares are owned by institutional investors. Comparatively, 90.5% of Abcam shares are owned by institutional investors. 7.6% of Century Therapeutics shares are owned by insiders. Comparatively, 6.7% of Abcam shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This table compares Century Therapeutics and Abcam’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Abcam beats Century Therapeutics on 7 of the 12 factors compared between the two stocks.
About Century Therapeutics
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-102, a CAR-iT targeting CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-107, an iPSC-derived Nectin-4 CAR gamma delta T-cell therapy product candidate; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company's principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.
Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.